[ad_1]
Call it wishful thinking or strategic amnesia, but just two years removed from its controversial decision ending a constitutional right to abortion, the Supreme Court is poised to decide another high-stakes appeal over nationwide access to the procedure.
At issue is the federal government’s approval process of the drug mifepristone, a medication used to terminate pregnancies.
Oral arguments are scheduled for Tuesday with a ruling expected about three months later, with the race for the next president in full swing.
MAJOR DRUG STORES START SELLING ABORTION PILL SOME SAY IS ‘DANGEROUS’ FOR WOMEN AHEAD OF LANDMARK SCOTUS CASE
Bottles of the abortion pills mifepristone, left, and misoprostol, right, at a clinic. (Charlie Neibergall)
While the case hinges on complex federal regulatory procedures, reproductive rights will again be the key question. It’s an appeal with enormous legal, social and political implications, and a high-stakes case following the court’s landmark ruling that struck down Roe v. Wade.
NATIONWIDE IMPACT
New data from the Guttmacher Institute research group indicates nearly two-thirds of all abortions in the U.S. in 2023 rely on mifepristone. Abortion rights groups say the drug has been proven safe and that the court’s decision could negatively impact 40 million women nationwide. Anti-abortion organizations counter that the U.S. Food and Drug Administration for two decades has unlawfully promoted a nationwide regime of on-demand abortion, in defiance of several state health and safety laws.
For now,…
[ad_2]
